NOVEL RADIOMETAL-BINDING COMPOUNDS FOR DIAGNOSIS OR TREATMENT OF PROSTATE SPECIFIC MEMBRANE ANTIGEN-EXPRESSING CANCER
申请人:PROVINCIAL HEALTH SERVICES AUTHORITY
公开号:US20200339625A1
公开(公告)日:2020-10-29
This application relates to compounds of Formula (I-a) or Formula (I-b), or is salts or solvates thereof. R
1
is —(CH
2
)
5
CH
3
or comprises 2-4 fused benzene rings. R
2
is I, Br, F, Cl, H, OH, OCH
3
, NH
2
, NO
2
or CH
3
. R
3
is a peptide-bonded glycine, aspartate or glutamate or is glutamate peptide bonded through C
delta
. L is —CH
2
NH—, —(CH
2
)
2
NH—, —(CH
2
)
3
NH—, or —(CH
2
)
4
NH—. R
4
is a radiometal chelator optionally bound by a radiometal. Variable ‘n’ is 1-3. The compounds may be useful for imaging prostate specific membrane antigen (PSMA)-expressing tissues or for treating PSMA-expressing diseases (e.g. cancer).